

CLAIMS

1. Use of an agent cross-linking at least two molecules of the protein tyrosine phosphatase Sap-1 for the preparation of a medicament for treatment and/or prevention of cancer.
2. Use according to claim 1, wherein the cancer is a src-associated cancer.
3. Use according to claim 1, wherein the cancer is a gastrointestinal cancer.
4. Use according to claim 2 or 3, wherein the gastrointestinal cancer is selected from the group consisting of esophageal tumor, stomach cancer, small-bowel tumor, large-bowel tumor, and pancreatic cancer.
5. Use according to any of the preceding claims wherein the cross-linking agent is a proteinaceous cross-linker.
6. Use according to claim 5, wherein the proteinaceous cross-linker is an antibody directed against the extra-cellular domain of Sap-1.
7. Use according to claim 6, wherein the antibody is directed against a Fibronectin-type III like domain of Sap-1.
8. Use according to claims 5 or 6, wherein the cross-linking agent is a monoclonal antibody.
9. Use according to claim 8, wherein the cross-linking agent is a humanized antibody.
10. Use according to claim 8, wherein the cross-linking agent is a human antibody.
11. Use according to claim 5, wherein the cross-linking agent is a soluble fragment of the extracellular domain of Sap-1.
12. Use according to claim 11, wherein the cross-linking agent comprises one, two, three, four, five, six, seven or eight Fibronectin-type III like repeats of Sap-1.
13. Use according to any of claims 5 to 12, wherein the cross-linking agent is a mutein, fused protein, functional derivative, active fraction or salt of the proteinaceous cross-linking agent.
14. Use according to any of the preceding claims, wherein the cross-linking agent is a functional derivative comprising at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.
15. Use according to claim 14, wherein the moiety is a polyethylene moiety.